文献速递创伤骨科骨质疏松与代谢性骨病

术前继续口服抗凝药或抗血小板药对老年髋部骨折患者健康结局的影响:系统综述与荟萃分析

Effects of pre-operative continuing oral anticoagulants or antiplatelets on health outcomes among older patients with hip fracture: a systematic review and meta-analysis.
PubMed 文献 · Osteoporos Int · 2025-08-07

该系统综述与荟萃分析纳入13项观察性研究、885例≥65岁服用抗血小板药或直接口服抗凝药(DOACs)的髋部骨折患者,比较继续与停用药物、或早期与延迟手术的结局。继续抗血小板药者的输血率无显著差异(OR=0.87,95%CI 0.37–2.03);停用抗血小板药后48小时内手术与住院时间缩短相关(均差=-5.71天,95%CI -8.36至-3.06),输血和院内死亡率未增加。DOAC使用者早期与延迟手术的输血和30天死亡率无显著差异。作者结论认为不停用抗血小板药手术可能安全,停用后早期手术可缩短住院时间且无不良结局,需随机试验确认。

要点

  • 继续抗血小板药手术的输血率与停药者无显著差异(OR=0.87,95%CI 0.37–2.03)。
  • 停用抗血小板药后48小时内手术较延迟手术住院时间缩短5.71天(95%CI -8.36至-3.06)。
  • DOAC使用者早期与延迟手术的输血和30天死亡率无显著差异。

核心结论

  • 不停用抗血小板药进行手术可能安全。
  • 停用抗血小板药后早期手术可能缩短住院时间且无不良结局。
  • 需要随机试验确认这些发现。

研究设计与样本

  • 系统综述与荟萃分析,纳入13项观察性研究,来自9个国家,共885例患者。
  • 纳入≥65岁服用抗血小板药或DOACs的髋部骨折患者,比较继续与停用药物、或早期与延迟手术。
  • 检索MEDLINE、EMBASE、Cochrane Library和Web of Science至2024年11月。
  • 使用纽卡斯尔-渥太华量表评估偏倚风险,采用随机效应模型合并效应估计。
  • 研究注册于PROSPERO(CRD42022378334)。

主要发现

  • 继续用药者输血率无显著差异(OR=0.87;95%CI 0.37–2.03)。
  • 停用抗血小板药后48小时内手术较延迟手术住院时间缩短(均差=-5.71天;95%CI -8.36至-3.06),输血(OR=0.75;95%CI 0.04–13.73)和院内死亡率(OR=0.49;95%CI 0.02–13.52)未增加。
  • DOAC使用者早期与延迟手术的输血(OR=1.09;95%CI 0.56–2.09)和30天死亡率(OR=1.53;95%CI 0.45–5.19)无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 停用抗血小板药或DOACs后及时手术的可行性尚需进一步研究。
  • 需要随机试验确认这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Continuing antiplatelets during hip fracture surgery may be safe for older adults, while early surgery after discontinuation reduces hospital stay without adverse outcomes. PURPOSE: The safety of continuing antiplatelets or direct oral anticoagulants (DOACs) before surgery in older patients with hip fractures remains uncertain. The feasibility of timely surgery after discontinuation also warrants further investigation. METHODS: We included studies of hip fracture patients aged ≥ 65 years taking antiplatelets or DOACs, comparing continuation versus discontinuation, or early versus delayed surgery. MEDLINE, EMBASE, Cochrane Library, and Web of Science were searched to November 2024. Risk of bias was assessed using the Newcastle-Ottawa Scale. Meta-analyses were conducted using a random-effects model to pool effect estimates. This study was registered with PROSPERO (CRD42022378334). RESULTS: Thirteen observational studies from nine countries involving 885 patients were included. There were no significant differences in transfusion rates in patients who continued the medication (Odds Ratio [OR] = 0.87; 95% Confidence Interval [CI]: 0.37 to 2.03). Surgery within 48 h of antiplatelet discontinuation was associated with shorter hospital stay (mean difference = - 5.71 days; 95% CI: - 8.36 to - 3.06) compared to those with delayed surgery, with no increase in transfusion (OR = 0.75; 95% CI: 0.04 to 13.73) and in-hospital mortality (OR = 0.49; 95% CI: 0.02 to 13.52). For DOAC users, no significant differences were observed in transfusion (OR = 1.09; 95% CI: 0.56 to 2.09) and 30-day mortality (OR = 1.53; 95% CI: 0.45 to 5.19) for early versus delayed surgery. CONCLUSIONS: Surgery without discontinuing antiplatelets may be safe. Early surgery after discontinuing antiplatelets could reduce hospital stays without adverse outcomes. Randomized trials are needed to confirm these findings.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Tang N, Zhang J, Liu X, et al. Effects of pre-operative continuing oral anticoagulants or antiplatelets on health outcomes among older patients with hip fracture: a systematic review and meta-analysis. Osteoporos Int. 2025. PMID: 40775083. doi:10.1007/s00198-025-07572-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。